Brodalumab

DB11776ApprovedInvestigationalProtein Based TherapiesInterleukin-17 Receptor A Antagonist

Brodalumab is a monoclonal antibody used to treat moderate to severe plaque psoriasis. Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis.

Mechanism
Curator reviewed
Primary indication
Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.Curator reviewed · 2 structured indications
First approval
Canada, 2019 · United States, 2017 · European Union, 2020
Code names
AMG-827 · KHK-4827
Brand names
  • Kyntheum
  • Siliq

Resolves to

Compound
UNII6ZA31Y954ZCAS1174395-19-7KEGGD10061
Clinical / RWD
RxNorm1872251ATCL04AC12
Targets
Q96F46IL17RAQ9NRM6IL17RBQ8NAC3IL17RCQ8NFM7IL17RDQ8NFR9IL17REQ16552IL17A

What you can answer from here — as of June 15, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
687Drug interactionsStructured to mechanism, not free text
Sign in
45Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
8Marketed productsAcross 6 countries and 4 labellers
Sign in
1ATC codeIncluding every combination product, plus 16 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Brodalumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In